Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix(Universitat de Barcelona), Josep M. Llovet(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Guido Gerken, Camillo Porta(University of Pavia), Angelo Sangiovanni(Ospedale Maggiore), D. Voliotis(Bayer (United States)), Andrea Nadel(Bayer (United States)), Morris Sherman(Nihon University), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Peter R. Galle, Jean‐Luc Raoul(Université Européenne de Bretagne), Antonio Craxı̀(University of Palermo), Armando Santoro(IRCCS Humanitas Research Hospital), Michel Beaugrand(Biomedical Research Institute), Michael Shan(Bayer (United States)), M. Moscovici(Bayer (Italy)), Luigi Bolondi(University of Bologna), Jorge A. Marrero(The University of Texas Southwestern Medical Center)
Cited by 821
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.1k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k